Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth

Cancer Biology and Therapy

Volumn 4, Issue 11, 2005, Pages 1275-1284

  Hawkins, William ^a   Mitchell, Clint ^a   McKinstry, Robert ^a   Gilfor, Donna ^a   Starkey, James ^a   Dai, Yun ^a   Dawson, Kathy ^a   Ramakrishnan, Viswanathan ^a   Roberts, John D ^a,b   Yacoub, Adly ^a   Grant, Steven ^a,b   Dent, Paul ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cell death; MEK1 2; Tumor control

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 7 HYDROXYSTAUROSPORINE; CD31 ANTIGEN; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CELL DEATH; CELL STRAIN MCF 7; COLONY FORMATION; CONTROLLED STUDY; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PHOSPHORYLATION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

EID: 33646398132     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.11.2286     Document Type: Article

References (50)

1. Mow BM, Blajeski AL, Chandra J, Kaufmann SH. Apoptosis and the response to anticancer therapy. Curr Opin Onool 2001; 13:453-62.
2. Mizuno K, Noda K, Ueda Y, Hanaki H, Saido TC, Ikuta T, Kuroki T, Tamaoki T, Hirai S, Osada S UCN-01, an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily. FEBS Lett 1995; 359: 259-261.
3. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000; 275: 5600-5.
4. Peng C-Y, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277: 1501-5.
5. Komander D, Kular GS, Bain J, Elliott M, Alessi DR, Van Aalten DM. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J 2003; 375:255-62.
6. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000; 60:2108-12.
7. 2 checkpoint inhibitor. Clin Cancer Res 1996; 2:791-7.
8. Tang L, Boise LH, Dent P, Grant S. Potentiation of 1-beta-D- arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). Biochem Pharmacol 2000; 60:1445-56.
9. Shao R-G, Cao C-X, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997; 57: 4029-35.
10. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Diff 1995; 6:927-36.
11. Tombes R, Auer KL, Mikkelsen R, Valerie K, Wymann MP, Marshall CJ, McMahon M, Dent P. The mitogen_activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic Biochem J 1998; 330: 1451-60.
12. Park JS, Boyer S, Mitchell K, Gilfor D, Birrer M, Darlington G, El Deiry W, Firestone GL, Munger K, Band V, Fisher PB, Dent P. Expression of human papilloma virus E7 protein causes apoptosis and inhibits DNA synthesis in primary hepatocytes via increased expression of p21 Cip- 1/WAF1/mda6. J Biol Chem 2000; 274: 18-28.
13. Vrana J, Grant S, Dent P. MAPK and JNK1 activities in HL-60 cells overexpresing Bcl-2 after exposure to ionizing radiation; possible roles of these pathways in leukemic cell survival. Radiation Res 1999; 151:559-69.
14. 2/M transition induced by nocodazole. J Biol Chem 2000; 275:31876-82.
15. Carter S, Auer KL, Reardon DB, Birrer M, Fisher PB, Valerie K, Schmidt-Ullrich R, Mikkelsen R, Dent P. Potentiation of Ionizing Radiation induced cell killing by inhibition of the Mitogen Activated Protein (MAP) kinase cascade in A431 human squamous carcinoma cells. Oncogene 1998; 16: 2787-96.
16. Jarvis WD, Fornari FA, Tombes RM, Erukulla RK, Bittman R, Schwartz GK, Dent P, Grant S. Chemo-potentiation of 1-≤-D-arabino-furanosy lcytosine-related cytotoxicity in human myeloid leukemia cells by pharmacological modulation of protein kinase C and mitogen-activated protein kinase. Mol Pharm 1998; 54: 844-56.
17. Wang S, Guo CY, Dent P, Grant S. Effect of Bcl-XL expression on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Leukemia 1999; 13:1564-73.
18. Park JS, Carter S, Reardon DB, Schmidt-Ullrich R, Dent P, Fisher PB. Mitogen Activated Protein (MAP) kinase pathway signaling is required for release / progression of cells through G2/M after exposure to ionizing radiation. Mol Biol Ceil 1999; 10: 4215-31.
19. Wang Z, VanTuyle G, Conrad D, Fisher PB, Dent P, Grant S. Dysregulation of the cyclin dependent kinase inhibitor p21 WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-b-D-arabinofuranosylcytosine- mediated mitochondrial dysfunction and apoptosis. Cancer Res 1999; 59: 1259-67.
20. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. MAPK pathways in radiation responses. Oncogene 2003; 22:5885-96.
21. Dent P, Qiao L, Grant S. Signaling by ErbB family receptors. Frontiers in Bioscience 2002; D376-89.
22. McKinstry R, Qiao L, Dai Y, Fisher PB, Grant S, Dent P. Pharmacologic inhibitors of the mitogen activated protein kinase cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in mammary and prostate carcinoma cells. Cancer Biology and Therapy 2002; 1:241-51.
23. Dai Y, Decker RH, McKinstry R, Dent P, Grant S. Pharmacologic inhibitors of the mitogen activated protein kinase cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in leukemia and lymphoma cells. Cancer Res 2001; 61:5106-15.
24. Dai Y, Landowski TH, Rosen ST, Dent P, Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 2002; 100:3333-43.
25. Yu C, Dai Y, Dent P, Grant S. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571. Cancer Biol Ther 2002; 1:674-82.
26. Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C, Dent P, Grant S. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 2005; 105:1706-16.
27. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, Grant S. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 2003; 63:1822-33.
28. Gao N, Dai Y, Rahmani M, Dent P, Grant S. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol 2004; 66:956-63.
29. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, Spiegel S, Grant S. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005; 65:2422-32.
30. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 2002; 62:188-99.
31. Brust D, Feden J, Farnsworth J, Amir C, Broaddus WC, Valerie K. Radiosensitization of rat glioma with bromodeoxycytidine and adenovirus expressing herpes simplex virus-thymidine kinase delivered by slow, rate-controlled positive pressure infusion. Cancer Gene Ther 2000; 7:778-88.
32. Patel V, Lahusen T, Leethanakul C, Igishi T, Kremer M, Quintanilla-Martinez L, Ensley JF, Sausville EA, Gutkind JS, Senderowicz AM. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1). Clin Cancer Res 2002; 8:3549-60.
33. Pei XY, Dai Y, Rahmani M, Li W, Dent P, Grant S. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. Clin Cancer Res 2005; 11:4589-600.
34. Reinehr R, Becker S, Hongen A, Haussinger D. The Src family kinase Yes triggers hyperosmotic activation of the epidermal growth factor receptor and CD95. J Biol Chem 2004; 279:23977-87.
35. Gulli LF, Palmer KC, Chen YQ, Reddy KB. Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ 1996; 7:173-8.
36. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5:810-6.
37. McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Perez-Soler R, Horwitz SB. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor Cl-1040 in nude mice bearing human heterotransplants. Cancer Res 2005; 65:2854-60.
38. Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD, Arbuck SG, Senderowicz AM, Fuse E, Tanii H, Kuwabara T, Kobayasbi S. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models. Cancer Chemother Pharmacol 1998; 42:S54-59.
39. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 1998; 58:3248-53.
40. Hagenauer B, Maier-Salamon A, Thalhammer T, Zollner P, Senderowicz A, Jager W. Metabolism of UCN-01 in isolated perfused rat liver: Role of Mrp2 in the biliary excretion of glucuronides. Oncol Rep 2004; 11:1069-75.
41. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB. Multicenter phase II study of the oral MEK inhibitor, Cl-1040, in patients with advanced nonsmall-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22:4456-62.
42. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, Deluca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB. Phase I and Pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23:5281-93.
43. Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005; 5:350-6.
44. Kronblad A, Hedenfalk I, Nilsson E, Pahlman S, Landberg G. ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ER alpha: A combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene 2005; 24:6835-41.
45. Kirsch DG, Loeffler JS. Brain metastases in patients with breast cancer: New horizons. Clin Breast Cancer 2005; 6:115-24.
46. Heys SD, Sarkar T, Hutcheon AW. Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer. Expert Opin Pharmacother 2004; 5:2147-57.
47. Yacoub A, Han SI, Caron R, Gilfor D, Mooberry S, Grant S, Dent P. Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. Cancer Biol Ther 2003; 2:670-6.
48. Kruger EA, Blagosklonny MV, Dixon SC, Figg WD. UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response. Invasion Metastasis 1998-99; 18:209-18.
49. Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M, Rizzoli V, Bonati A. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia 2004; 18:628-35.
50. Park JS, Qiao L, Su ZZ, Hinman D, Willoughby K, McKinstry R, Yacoub A, Duigou GJ, Young CS, Grant S, Hagan MP, Ellis E, Fisher PB, Dent P. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 2001; 20:3266-80.